<DOC>
	<DOCNO>NCT01079676</DOCNO>
	<brief_summary>This study primary objective endpoint compare efficacy two product contain filgrastim , evaluate formulation produce Eurofarma consider non-inferior reference product .</brief_summary>
	<brief_title>A Non-inferiority Study Comparing Two Filgrastim Preparations Breast Cancer</brief_title>
	<detailed_description>This study primary objective endpoint compare efficacy two product contain filgrastim , evaluate formulation produce Eurofarma consider non-inferior reference product . For , study primary endpoint rate grade 4 neutropenia first cycle chemotherapy , accord classification Common Terminology Criteria Adverse Events ( CTC-AE ) . The study secondary objective compare efficacy aspect , well tolerability two product contain filgrastim . The secondary endpoint consider study : - The febrile neutropenia rate ; - The rate grade 4 neutropenia ; - The duration grade 4 neutropenia ; - The frequency adverse event laboratory change .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Signed ICF ; Diagnosis confirm anatomic pathology examination ( cytology histopathology ) breast cancer ; Clinical image confirmation stage II IV disease , accord TNM classification ; Indication chemotherapy one eligible regimen , long treatment first cycle plan full dose ( without adjustment relative original regimen ) ; Performance status 0 1 Zubrod scale ; No one previous chemotherapeutic regimen metastatic disease ; Proper organic function , indicate following condition : ANC &gt; 1500/mm3 ; Platelet count &gt; 150000/mm3 ; Serum creatinine &lt; 1,2 mg/dL ; Bilirubins transaminase ( aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] ) &lt; 1.5 time upper limit normal . Forecast prophylactic therapeutic use antibiotic , antifungal antiviral first cycle chemotherapy ; Previous radiotherapy involve pelvis radiotherapy site last 6 week randomization ; History bone marrow transplantation ( receptor ) ; Presence neoplasia , exception situ cervical carcinoma , situ bladder carcinoma , cutaneous basal cell carcinoma properly treat , cutaneous spinocellular carcinoma properly treat , T1 vocal cord cancer remission previous malignant neoplasia treat 5 year recruitment without relapse ; Presence severe comorbidities , cardiovascular , chronic respiratory , kidney , liver , neurological , hematological , infectious , skin , neurological psychiatric disease ; Recent ( &lt; 12 month ) foresee participation study clinical study involve nature drug study kind intervention , unless may direct benefit research subject , per CNS/MS Resolution 251/97 , item III.j . Intolerability allergy component filgrastim formulation evaluate study . Pregnancy lactation ( patient childbearing potential must negative blood pregnancy test 7 day prior randomization ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>